Wandercraft Announces Acquisition of Ekso Bionics, Uniting Two Pioneers to Advance and Expand Robotic Mobility

Wandercraft has acquired Ekso Bionics, bringing together two pioneers in robotic mobility to expand access to medical exoskeletons worldwide.

Wandercraft has announced the acquisition of Ekso Bionics, Inc. from a subsidiary of ChronoScale Holdings Corporation (Nasdaq: CHRN), bringing together two leaders in robotic mobility. The two companies contribute complementary technologies and decades of combined experience aimed at helping more people stand, walk and participate more fully in everyday life. Together, they form what the companies describe as the world’s leading medical exoskeleton company, combining technology, clinical experience and global reach.

The acquisition combines Wandercraft’s expertise in advanced robotics and physical AI and its leadership in EMEA with Ekso Bionics’ strong US presence, extensive clinical experience and commercial reach. Both companies have been pioneers in medical exoskeletons, driving technological innovation, R&D and clinical research. The combination creates a global robotic mobility company with a broader portfolio of medical exoskeletons spanning the continuum of care, from rehabilitation to everyday personal mobility.

“We share a vision for how robotics can empower people whose mobility has been unfairly limited by injury or disease,” said Matthieu Masselin, CEO and co-founder of Wandercraft. “Both companies have pioneered advanced technologies to help people stand, walk, and participate more fully in everyday life. By bringing together our products, teams, and clinical relationships on both sides of the Atlantic, we have an exceptional opportunity to expand access to robotic mobility worldwide, reach more patients and rehabilitation professionals, and help more people experience the independence and connection that upright mobility can offer.”

Atalante X and EksoNR currently support patients in standing and walking at more than 700 rehabilitation centres worldwide. Together, the two platforms hold US FDA clearances and CE marking covering stroke, spinal cord injury, multiple sclerosis and acquired brain injury. For personal use, Eve brings Wandercraft’s hands-free, self-balancing technology into the home, while Indego Personal offers a modular wearable exoskeleton for individuals with spinal cord injuries. Wandercraft intends to continue supporting all four products, along with the customers, clinicians and individuals who rely on them.

“Ekso has spent two decades pioneering robotic technologies, advancing engineering and R&D, and building a robust body of clinical research and evidence that has earned the trust of clinicians and the people who rely on our products,” said Scott Davis, CEO of Ekso Bionics. “Joining Wandercraft represents an exciting next chapter, uniting two organizations with a shared commitment to mobility, rehabilitation, and innovation. Together, we can build on that trailblazing work and expand our ability to develop and deploy technologies that make a meaningful difference for more people.”

The acquisition also reinforces Wandercraft’s position in expanding market access and deploying personal exoskeletons worldwide. Patients are already training at the Walk in New York by Wandercraft rehabilitation centre, and a dedicated access team helps users and their care teams navigate benefits, documentation, reimbursement, financing and coordination with clinicians and payers. In the US, Medicare covers qualifying personal exoskeletons for eligible individuals under its brace benefit category, billed under HCPCS code K1007, and the combined company plans to advocate for broader coverage worldwide.

The combination is also expected to strengthen customer service through a broader international network and shared clinical expertise, letting rehabilitation centres consult specialists with expertise in both Atalante X and EksoNR while maintaining dedicated, product-specific support.

The boards of directors of Wandercraft and ChronoScale Holdings Corporation unanimously approved the transaction, which was signed and closed simultaneously. Financial terms were not disclosed.

Source: Wandercraft